Australia's most trusted
source of pharma news
Friday, 03 July 2026
Posted 3 July 2026 AM
Last week the TGA approved Sanofi’s pegged blockbuster Altuviiio, adding to a growing list of haemophilia A treatment options in Australia, with the French pharma “working with urgency” to ensure equitable access, according to ANZ Country Lead and Head of Pharma, Liz Selby.
“The registration of Altuviiio marks an exciting milestone for the haemophilia community in Australia. It reflects Sanofi’s commitment to chasing the miracles of science that address unmet need,” Selby added.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.